• Earlier this week, Boston Scientific reported that its pivotal FRACTURE IDE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter met all primary safety and effectiveness endpoints in 420 patients with severely calcified coronary artery disease.
• The data showed high rates of freedom from major adverse cardiac events and consistent stent expansion in a particularly hard-to-treat patient group, supporting a regulatory submission for SEISMIQ 4CE.
• We’ll now examine how this positive FRACTURE trial outcome, especially the strong safety profile, could influence Boston Scientific’s existing investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Boston Scientific Investment Narrative Recap

To own Boston Scientific, you need to believe in its ability to keep launching differentiated cardiovascular devices and defend margins despite guidance cuts and competition in electrophysiology and WATCHMAN. The FRACTURE trial’s strong safety and effectiveness data for SEISMIQ 4CE slightly reinforces the short term catalyst of clinical momentum in cardiology, but it does not directly change the biggest near term risk around slower organic growth and execution across key franchises.

The most relevant recent announcement here is the company’s US$1.5 billion investment in MiRus and option on its TAVR assets, which, like SEISMIQ 4CE, sits in structural and coronary heart therapies. Together, SEISMIQ data and the MiRus stake highlight Boston Scientific’s focus on complex cardiovascular disease as a key growth driver, while the cut to 2026 organic revenue guidance reminds you that new technologies can take time to offset pressures in EP and WATCHMAN.

Yet behind the promising SEISMIQ data and MiRus deal, investors should also be aware of the risk that slower 6.5 to 8.0 percent 2026 organic growth guidance could...

Boston Scientific's narrative projects $26.3 billion revenue and $5.0 billion earnings by 2029. This requires 8.5% yearly revenue growth and an earnings increase of about $1.4 billion from $3.6 billion today.

Uncover how Boston Scientific's forecasts yield a $85.19 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming only about 6.9 percent annual revenue growth to roughly US$25.2 billion by 2029, so if SEISMIQ and related programs ramp slower than hoped, your view could end up closer to that more cautious path than the upbeat consensus that assumes faster margin gains and higher earnings power.

Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $83.47!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Boston Scientific research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.